Replies to post #3157 on Galectin Therapeutics Inc. (GALT)

[Amatuer17]

Yes they are very different trials but the 2nd trial is for an indicator which is progression of disease from 1st trial. So the same drug is trying to treat advance stage of disease.

So logical question is - if the drug was not successful in the early stage then why it will be successful in advance stage?

Few answers can be found in this blog by CEO

http://perspectives.galectintherapeutics.com/importance-completing-nash-cx-trial-for-patients-with-nash-cirrhosis/

As you can see - the CEO is very cautious on the expectations from the trial - it is a risky trial with low probability of success.

I suggested buying Jan 2018 calls as it reduces downside risk.
If there is success - the SP will really jump dramatically and give good returns - it is not limited to $3

The option allows you to buy the stock at $3 till Jan 2018 even if the price after Dec 2017 results go to say $6 or $8.